Petition for cancer treatment to be funded reaches 46,000 signatories
More than 46,000 people have signed a petition calling on the NHS to fund a life-changing cancer treatment for patients with neuroendocrine tumours (NETs).
The cancer charity Planets is leading the campaign for the treatment, known as selective internal radiation therapy (Sirt), to be made available through the NHS after it was approved for use more than a year ago.
A spokesman for the charity said: 'Every year approximately 6,000 people in the UK are diagnosed with NETs, a complex and often slow-growing cancer that can be difficult to detect and treat.
'Many patients develop tumours in the liver where the treatment could offer significant benefits.
'Sirt involves injecting millions of tiny radioactive beads called microspheres – smaller than the width of a human hair – into the blood supply in the liver to destroy cancer cells.'
The spokesman said that despite approval by the National Institute for Health and Care Excellence (NICE) in May 2024, NHS England had yet to commission it meaning that patients had no timetable for when it might become available.
He added that Sirt was already available on the NHS for patients whose liver cancer developed in the organ directly or which had spread to it from the bowel but NET patients remained excluded.
Layla Stephen, a NET patient from Hampshire and director of strategy and finance for Planets, said: ' Patients are missing out simply because of red tape.
'Without NHS commissioning, only those that can afford to go private have access to Sirt and that is simply not right or fair – we need to change this.'
Ms Stephen added: 'In a statement earlier this year, NHS England said it was developing a national policy on Sirt to ensure all patients across England have the best possible treatment, yet there is still no confirmed timeline despite approval in May last year, leaving patients in limbo and suffering agonising uncertainty.'
Caroline Nokes, Conservative MP for Romsey and Southampton North, has written to health and social care secretary Wes Streeting about the issue.
She said: 'Constituents of mine with neuroendocrine tumours should not be caught in a bureaucratic limbo when effective treatment is both available and approved. There needs to be fairness and transparency for these patients.'
An NHS spokeswoman said previously: 'The NHS understands the concerns raised about access to selective internal radiation therapy (Sirt) for neuroendocrine tumours in the liver.
'The health service is currently reviewing a clinical proposal and developing a new national mandated NHS policy on Sirt to ensure all patients across England have the best possible treatment for their liver metastases.'
The petition can be found at: change.org/p/ensure-access-for-cancer-patients-to-life-changing-treatment-approved-by-nice.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
3 hours ago
- Daily Mail
Father-of-four dies of bowel cancer, aged 40, within months of being diagnosed - the only warning sign was terrifyingly easy to dismiss
A father-of-four whose only sign of deadly bowel cancer was a troubling stomach ache has died, eight months after being told he had the disease. Kyle Ingram-Baldwin, 40, had only just launched a fundraiser on June 8 to pay for alternative treatments as he was 'not prepared to give up'. But in a heartbreaking post on the funding platform his wife Becky confirmed he had died on June 16. 'Unfortunately, Kyle took a very sudden and unexpected turn and we lost him yesterday,' she wrote. 'He was the most incredible man I have ever met, and I know he would want me to thank everyone for all your sharing and donations.' His death comes amid a worrying trend of younger adults being diagnosed with the devastating disease. Mr Ingram-Baldwin, from Minster, Kent, originally sought help from his GP in October after suffering a persistent stomach ache that he suspected was linked to stress or gallstones. But after the pain got worse he ended up attending A&E where scans revealed the true devastating cause. An ultrasound showed worrying bulges on his liver, with a follow-up CT scan confirming these were cancer. Further tests revealed these were secondary growths from a cancer that had originated in his bowel. This meant the disease was already at stage-four, the final and most serious stage. Only 10 per cent of bowel cancer patients diagnosed at stage four are alive five years later, according to Cancer Research UK. Recalling the moment he got the news Mr Ingram-Baldwin said the mental toll was extraordinary. 'I was thinking, what's going on here? What have I done wrong? I was putting the blame on my own feet and worrying about the future for my wife and kids,' he said. 'That's probably the hardest thing-the mental side. 'Don't get me wrong, the physical is not funny either, but it's a mental challenge.' Mr Ingram-Baldwin, who worked for a vending machine supplier, underwent more than half-a-dozen rounds of gruelling chemotherapy. But, unfortunately, this failed to bring the disease under control. Shortly before his death Mr Ingram-Baldwin spoke about how the cancer had impacted his wife, and children aged 12, nine, three and one. 'It's really hard to put into words, because I love my kids so much. You just worry about their future,' he said. 'They've got the best mum in the world, and I genuinely mean that. My wife's incredible.' He urged other patients to not dismiss signs that something isn't right in their bodies. 'I didn't present with any of the conventional symptoms,' he said. 'If you think anything's wrong, please press your GP and go get it checked, because I genuinely wouldn't want anyone being in my position.' Symptoms of the bowel cancer include changes in bowel movements such as diarrhoea or constipation, needing or feeling the need to empty your bowels more or less frequently, blood in stool, stomach pain, bloating, as well as unexpected weight loss and fatigue. Stomach pain like Mr Ingram-Baldwin experienced, a lump in the stomach, bloating and fatigue are also among other common signs. Mr Ingram-Baldwin isn't alone in being hit by a devastating bowel cancer diagnosis as a young adult. Experts have noted a concerning and mysterious rise in rates of the disease among young adults, defined in cancer terms as those under 50. A recent global study found rates of bowel cancer in under 50 year-olds are rising in 27 of 50 nations. England is averaging a 3.6 per cent rise in younger adults every year-one of the highest increases recorded. While the disease is known linked to obesity, experts have noted that the disease also seems to also be occurring in fit and healthy patients. Some experts believe the explanation must lie in environmental factors young people have been exposed to more than previous generations. While no 'smoking gun' has been found, there are multiple theories. These include modern chemicals in diets, microplastics, pollution, and one recent study even pinned the surge on exposure to in food. There are around 2,600 new bowel cancer cases in people aged 25-49 in Britain every year, and around 44,100 new cases among all ages. Around 44,000 cases of bowel cancer are diagnosed every year in the UK, with about 130,000 in the US. The disease kills almost 17,000 Britons each year, with the death toll rising to about 50,000 in America. Overall, just over half of bowel cancer patients are expected to be alive 10 years after their diagnosis. More than £15,000 was raised in Mr Ingram-Baldwin's drive for alternative treatments. Mrs Ingram-Baldwin has now confirmed the amount would now be re-funded to donors. She urged people to consider donating the money to charity or using it to 'make memories with your families'.
Leader Live
3 hours ago
- Leader Live
Alzheimer's drugs rejected for NHS because benefits ‘too small' to justify cost
The National Institute for Health and Care Excellence (Nice) is standing by its earlier decision to turn down donanemab and lecanemab after considering new information submitted by manufacturers. Charities described the decision as 'disappointing' and a 'painful setback' for patients, while the firms Lilly, which makes donanemab, and Eisai, which makes lecanemab, said they would appeal. Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer's. They represent a huge step forward in research because they target a known cause of the disease, rather than just treating symptoms. Both drugs bind to amyloid, a protein which builds up in the brains of people living with Alzheimer's disease. By binding to amyloid, the drugs are designed to help clear the build-up and slow down cognitive decline. Publishing its final draft guidance, Nice said the treatments have been shown to delay progression from mild to moderate Alzheimer's by four to six months. But it said the medicines cannot be provided on the NHS because they are not good value for money and 'only provide modest benefits at best'. Last year, NHS England published a briefing paper suggesting the cost of bringing the drugs to the health service could be £500 million to £1 billion per year. Professor Fiona Carragher, Alzheimer's Society's chief policy and research Officer, said the decision was 'disappointing'. She said: 'There is no doubt that today's decision is a setback for people with Alzheimer's disease. 'It is highly disappointing that we are in a situation where treatments that slow the progression of the condition are not available on the NHS. 'The reality we're faced with is that these treatments remain out of reach of both the NHS and most eligible people with Alzheimer's disease. 'In other diseases like cancer, treatments have become more effective, safer and cheaper over time. It's essential we see similar progress in dementia. 'The fact is, even if donanemab and lecanemab were made available on the NHS tomorrow, too many patients wouldn't be able to access them because the health system isn't ready to deliver them. 'The science is flying but the system is failing.' She said the Government must now commit to 'the long-term investment needed to fundamentally change dementia diagnosis so that we are ready for new treatments', including bringing in earlier diagnosis and access to specialist diagnostic tests. She added: 'We are heading towards a future where disease-slowing treatments reduce the devastating impact of dementia, and we cannot afford to delay preparing the NHS for them.' Hilary Evans-Newton, chief executive of Alzheimer's Research UK, said: 'This rejection is a painful setback for people affected by Alzheimer's – but sadly not a surprising one. 'The drugs' modest benefits, combined with the significant costs of delivering them in the NHS, meant they faced insurmountable challenges. 'People with early Alzheimer's in England and Wales now face a long wait for innovative new treatments as they won't be able to access lecanemab or donanemab unless they can afford to pay privately. 'This decision sends a troubling signal to the life sciences sector – undermining confidence in the UK as a home for research, innovation and clinical trials. That risks lasting damage to both patients and the economy. 'Nice's decision should ring alarm bells for a Government that, only a year ago, pledged to make the UK a global leader in dementia treatments. 'With over 30 Alzheimer's drugs now in late-stage trials globally, momentum is building – and more will enter regulatory systems in the years ahead. 'Without intervention from Government, people with Alzheimer's will continue to miss out — not because science is failing, but because the system is.' Helen Knight, director of medicines evaluation at Nice, said: 'While we recognise the hope these treatments offer, the evidence shows they only provide modest benefits at best and substantial resources would be needed to provide them. 'The committee accepted that any slowing of the disease getting worse would be meaningful for people with mild cognitive impairment or mild dementia caused by Alzheimer's disease and their carers because it could mean more time socialising, driving and being independent, so needing less help day-to-day from family members. 'But the committee concluded the small benefits to patients shown in the clinical trials and the lack of long-term evidence of effectiveness balanced with the substantial resources the NHS would need to commit to the treatments would be too great and could displace other essential treatments and services that deliver substantial benefits to patients. 'We have done everything we possibly can to try and achieve a positive outcome in our assessments of these treatments, including providing an additional opportunity for evidence to be submitted. 'We realise today's news will be disappointing for many, but we now need to focus on the encouraging pipeline of new Alzheimer's drugs in development, a number of which are already earmarked for Nice evaluation.' Drug firms and registered patient groups now have until July 8 to appeal against the decision. In clinical trials, donanemab, which is given via a drip, has been shown to slow the rate at which memory and thinking get worse by more than 20%. Results also suggest the drug leads to a 40% slowing in the decline of everyday activities such as driving, enjoying hobbies and managing money. Lecanemab – also administered via drip – has been shown to successfully remove protein build-up from the brains of people living with early Alzheimer's disease. For people taking lecanemab, this meant the decline in their thinking and memory skills was slowed down by 27%. It also slowed down the decline in quality of life by up to 56%. However, side-effects of the drugs can be serious, including brain bleeds and risk of death. A reformulation of lecanemab is being developed so it can be administered subcutaneously under the skin. Nice could then review the drug in this form. Lilly said it would appeal the Nice decision on the grounds it was unreasonable based on the evidence submitted. Chris Stokes, president and general manager of UK and Northern Europe at Lilly, said: 'If the system can't deliver scientific firsts to NHS patients, it is broken. 'If the Government is to deliver on its goals to reduce lives lost to the biggest killers and put Britain at the forefront of transforming treatment for dementia, it must keep pace with licensed medical breakthroughs.' Dr Jeremy Isaacs, national clinical director for dementia at NHS England, said: 'NHS England has a dedicated team preparing for the rollout of new Alzheimer's treatments. 'There are several other Alzheimer's treatments in development, and the NHS stands ready to offer patients access to new treatments as soon as they are deemed by regulators to be clinically and cost effective.'
North Wales Chronicle
3 hours ago
- North Wales Chronicle
Alzheimer's drugs rejected for NHS because benefits ‘too small' to justify cost
The National Institute for Health and Care Excellence (Nice) is standing by its earlier decision to turn down donanemab and lecanemab after considering new information submitted by manufacturers. Charities described the decision as 'disappointing' and a 'painful setback' for patients, while the firms Lilly, which makes donanemab, and Eisai, which makes lecanemab, said they would appeal. Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer's. They represent a huge step forward in research because they target a known cause of the disease, rather than just treating symptoms. Both drugs bind to amyloid, a protein which builds up in the brains of people living with Alzheimer's disease. By binding to amyloid, the drugs are designed to help clear the build-up and slow down cognitive decline. Publishing its final draft guidance, Nice said the treatments have been shown to delay progression from mild to moderate Alzheimer's by four to six months. But it said the medicines cannot be provided on the NHS because they are not good value for money and 'only provide modest benefits at best'. Last year, NHS England published a briefing paper suggesting the cost of bringing the drugs to the health service could be £500 million to £1 billion per year. Professor Fiona Carragher, Alzheimer's Society's chief policy and research Officer, said the decision was 'disappointing'. She said: 'There is no doubt that today's decision is a setback for people with Alzheimer's disease. 'It is highly disappointing that we are in a situation where treatments that slow the progression of the condition are not available on the NHS. 'The reality we're faced with is that these treatments remain out of reach of both the NHS and most eligible people with Alzheimer's disease. 'In other diseases like cancer, treatments have become more effective, safer and cheaper over time. It's essential we see similar progress in dementia. 'The fact is, even if donanemab and lecanemab were made available on the NHS tomorrow, too many patients wouldn't be able to access them because the health system isn't ready to deliver them. 'The science is flying but the system is failing.' She said the Government must now commit to 'the long-term investment needed to fundamentally change dementia diagnosis so that we are ready for new treatments', including bringing in earlier diagnosis and access to specialist diagnostic tests. She added: 'We are heading towards a future where disease-slowing treatments reduce the devastating impact of dementia, and we cannot afford to delay preparing the NHS for them.' Hilary Evans-Newton, chief executive of Alzheimer's Research UK, said: 'This rejection is a painful setback for people affected by Alzheimer's – but sadly not a surprising one. 'The drugs' modest benefits, combined with the significant costs of delivering them in the NHS, meant they faced insurmountable challenges. 'People with early Alzheimer's in England and Wales now face a long wait for innovative new treatments as they won't be able to access lecanemab or donanemab unless they can afford to pay privately. 'This decision sends a troubling signal to the life sciences sector – undermining confidence in the UK as a home for research, innovation and clinical trials. That risks lasting damage to both patients and the economy. 'Nice's decision should ring alarm bells for a Government that, only a year ago, pledged to make the UK a global leader in dementia treatments. 'With over 30 Alzheimer's drugs now in late-stage trials globally, momentum is building – and more will enter regulatory systems in the years ahead. 'Without intervention from Government, people with Alzheimer's will continue to miss out — not because science is failing, but because the system is.' Helen Knight, director of medicines evaluation at Nice, said: 'While we recognise the hope these treatments offer, the evidence shows they only provide modest benefits at best and substantial resources would be needed to provide them. 'The committee accepted that any slowing of the disease getting worse would be meaningful for people with mild cognitive impairment or mild dementia caused by Alzheimer's disease and their carers because it could mean more time socialising, driving and being independent, so needing less help day-to-day from family members. 'But the committee concluded the small benefits to patients shown in the clinical trials and the lack of long-term evidence of effectiveness balanced with the substantial resources the NHS would need to commit to the treatments would be too great and could displace other essential treatments and services that deliver substantial benefits to patients. 'We have done everything we possibly can to try and achieve a positive outcome in our assessments of these treatments, including providing an additional opportunity for evidence to be submitted. 'We realise today's news will be disappointing for many, but we now need to focus on the encouraging pipeline of new Alzheimer's drugs in development, a number of which are already earmarked for Nice evaluation.' Drug firms and registered patient groups now have until July 8 to appeal against the decision. In clinical trials, donanemab, which is given via a drip, has been shown to slow the rate at which memory and thinking get worse by more than 20%. Results also suggest the drug leads to a 40% slowing in the decline of everyday activities such as driving, enjoying hobbies and managing money. Lecanemab – also administered via drip – has been shown to successfully remove protein build-up from the brains of people living with early Alzheimer's disease. For people taking lecanemab, this meant the decline in their thinking and memory skills was slowed down by 27%. It also slowed down the decline in quality of life by up to 56%. However, side-effects of the drugs can be serious, including brain bleeds and risk of death. A reformulation of lecanemab is being developed so it can be administered subcutaneously under the skin. Nice could then review the drug in this form. Lilly said it would appeal the Nice decision on the grounds it was unreasonable based on the evidence submitted. Chris Stokes, president and general manager of UK and Northern Europe at Lilly, said: 'If the system can't deliver scientific firsts to NHS patients, it is broken. 'If the Government is to deliver on its goals to reduce lives lost to the biggest killers and put Britain at the forefront of transforming treatment for dementia, it must keep pace with licensed medical breakthroughs.' Dr Jeremy Isaacs, national clinical director for dementia at NHS England, said: 'NHS England has a dedicated team preparing for the rollout of new Alzheimer's treatments. 'There are several other Alzheimer's treatments in development, and the NHS stands ready to offer patients access to new treatments as soon as they are deemed by regulators to be clinically and cost effective.'
